| trastuzumab based treatment |
| trastuzumab plus endocrine therapy | trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel |
es-BC - HER2 negative - (neo)adjuvant (NA) 1 | | |
es-BC - HER2 positive - (neo)adjuvant (NA) 4 | | |
la/mBC - HER2 positive | | |
la/mBC - HER2 positive - (neo)adjuvant (NA) | | |
la/mBC - HER2 positive - 1st Line (L1) 5 | | |
la/mBC - HER2 positive - 2nd Line (L2) 13 | | |